Principles of Drug Metabolism

Total Page:16

File Type:pdf, Size:1020Kb

Principles of Drug Metabolism PRINCIPLES OF DRUG METABOLISM In pharmacology, one speaks of pharmaco- dynamic effects to indicate what a drug does to the body, and pharmacokinetic effects to indi- BERNARD TESTA Department of Pharmacy, University Hospital cate what the body does to a drug, two aspects Centre, CH-1011 Lausanne, Switzerland of the behavior of drugs that are strongly inter- dependent. Pharmacokinetic effects will ob- viously have a decisive influence on the 1. INTRODUCTION intensity and duration of pharmacodynamic effects, while metabolism will generate new Xenobiotic metabolism, which includes drug chemical entities (metabolites) that may metabolism, has become a major pharmacolo- have distinct pharmacodynamic properties of gical science with particular relevance to biol- their own. Conversely, by its own pharmaco- ogy, therapeutics and toxicology. Drug meta- dynamic effects, a compound may affect the bolism is also of great importance in medicinal state of the organism (e.g., hemodynamic chemistry because it influences in qualitative, changes, enzyme activities, etc.) and hence the quantitative, and kinetic terms the deactiva- organism’s capacity to handle xenobiotics. tion, activation, detoxification, and toxifica- Only a systemic approach can help one appreci- tion of the vast majority of drugs. As a result, ate the global nature of this interdependence. medicinal chemists engaged in drug discovery and development should be able to integrate metabolic considerations into drug design. To 1.2. Types of Metabolic Reactions Affecting do so, however, requires a fair or even good Xenobiotics knowledge of xenobiotic metabolism. A first discrimination to be made among me- This chapter, which is written by a medic- tabolic reactions is based on the nature of the inal chemist for medicinal chemists, aims at catalyst. Reactions of xenobiotic metabolism, offering knowledge and understanding rather like other biochemical reactions, are than encyclopedic information. Readers want- catalyzed by enzymes. However, while the vast majority ing to go further in the study of xenobiotic of reactions of xenobiotic metabolism are in- metabolism may consult various classical or deed enzymatic ones, some recent books [1–15], broad reviews, and book nonenzymatic re- actions are also well documented. This is due chapters [16–27]. to the fact that a variety of xenobiotics have been found to be labile enough to react none- 1.1. Definitions and Concepts nzymatically under biological conditions of Drugs are but one category among the many pH and temperature [28]. But there is more. xenobiotics (Table 1) that enter the body but In a normal enzymatic reaction, metabolic have no nutritional or physiological value [14]. intermediates exist en route to the product The study of the disposition—or fate—of xe- (s) and do not leave the catalytic site. However, nobiotics in living systems includes the con- many exceptions to this rule are known, with sideration of their absorption into the organ- the metabolic intermediate leaving the active ism, how and where they are distributed and site and reacting with water, with an endo- stored, the chemical and biochemical trans- genous molecule or macromolecule, or with a formations they may undergo, and how and xenobiotic. Such reactions are also of a none- by which route(s) they are finally excreted nzymatic nature but are better designated as and returned to the environment. As for postenzymatic reactions. “metabolism,” this word has acquired two The metabolism of drugs and other xeno- meanings, being synonymous with disposition biotics is often a biphasic process in which the (i.e., the sum of the processes affecting the fate compound may first undergo a functionaliza- of a chemical substance in the body), and with tion reaction (phase I reaction) of oxidation, biotransformation as understood in this reduction, or hydrolysis. This introduces or chapter. unveils a functional group such as a hydroxy 405 Burger’s Medicinal Chemistry, Drug Discovery, and Development, Seventh Edition, edited by Donald J. Abraham and David P. Rotella Copyright Ó 2010 John Wiley & Sons, Inc. 406 PRINCIPLES OF DRUG METABOLISM Table 1. Major Categories of Xenobiotics 1.3. Specificities and Selectivities (Modified from Ref. [14]) in Xenobiotic Metabolism . Drugs The words “selectivity” and “specificity” may . Food constituents devoid of physiological roles not have identical meanings in chemistry and . Food additives (preservatives, coloring and fla- biochemistry. In this chapter, the specificity of voring agents, antioxidants, etc.) . Chemicals of leisure, pleasure, or abuse (ethanol, an enzyme is taken to mean an ensemble of coffee and tobacco constituents, hallucinogens, properties, the description of which makes it doping agents, etc.) possible to specify the enzyme’s behavior. In . Agrochemicals (fertilizers, insecticides, herbicides, contrast, the term selectivity is applied to etc.) metabolic processes, indicating that a given . Industrial and technical chemicals (solvents, dyes, metabolic reaction or pathway is able to select monomers, polymers, etc.) some substrates or products from a larger set. Pollutants of natural origin (radon, sulfur dioxide, In other words, the selectivity of a metabolic hydrocarbons, etc.) reaction is the detectable expression of the . Pollutants produced by microbial contamination specificity of an enzyme. Such definitions may (e.g., aflatoxins) . Pollutants produced by physical or chemical not be universally accepted, but they have the transformation of natural compounds (polycyclic merit of clarity. aromatic hydrocarbons by burning, Maillard re- What, then, are the various types of selec- action products by heating, etc.) tivities (or specificities) encountered in xeno- biotic metabolism? What characterizes an en- zyme from a catalytic viewpoint is first its chemospecificity, that is, its specificity in terms of the type(s) of reaction it catalyzes. When two or more substrates are metabolized or amino group suitable for coupling with an at different rates by a single enzyme under endogenous molecule or moiety in a second identical conditions, substrate selectivity is metabolic step known as a conjugation reac- observed. In such a definition, the nature of tion (phase II reaction) [19,24]. In a number of the product(s) and their isomeric relationship cases, phase I metabolites may be excreted are not considered. Substrate selectivity is prior to conjugation, while many xenobiotics distinct from product selectivity, which is ob- can be directly conjugated. Furthermore, re- served when two or more metabolites are actions of functionalization may follow some formed at different rates by a single enzyme reactions of conjugation, for example, some from a single substrate. Thus, substrate-se- conjugates are hydrolyzed and/or oxidized lective reactions discriminate between differ- prior to their excretion. ent compounds, while product-selective reac- Xenobiotic biotransformation thus pro- tions discriminate between different groups or duces two types of metabolites, namely func- positions in a given compound. tionalization products and conjugates. But The substrates being metabolized at differ- with the growth of knowledge, biochemists ent rates may share various types of relation- and pharmacologists have progressively come ships. They may be chemically dissimilar or to recognize the existence of a third class of similar (e.g., analogs), in which case the term metabolites, namely xenobiotic–macromole- of substrate selectivity is used in a narrow cule adducts, also called macromolecular con- sense. Alternatively, the substrates may be jugates. Such peculiar metabolites are formed isomers such as positional isomers (regioi- when a xenobiotic binds covalently to a biolo- somers) or stereoisomers, resulting in sub- gical macromolecule, usually following meta- strate regioselectivity or substrate stereose- bolic activation (i.e., postenzymatically). Both lectivity. Substrate enantioselectivity is a par- functionalization products and conjugates ticular case of the latter (see Section 4.2.1). have been found to bind covalently to biologi- Products formed at different rates in pro- cal macromolecules, the reaction often being duct-selective reactions may also share var- toxicologically relevant. ious types of relationships. Thus, they may be INTRODUCTION 407 analogs, regioisomers, or stereoisomers, re- one of toxification. Such a metabolite may act sulting in product selectivity (narrow sense), or react in a number of ways to elicit a variety product regioselectivity, or product stereose- of toxic responses at different biological levels. lectivity (e.g., product enantioselectivity). However, it is essential to stress that the Note that the product selectivity displayed by occurrence of a reaction of toxification (i.e., two distinct substrates in a given metabolic toxicity at the molecular level) does not neces- reaction may be different, in other words the sarily imply toxicity at the levels of organs and product selectivity may be substrate-selective. organisms, as discussed later in this chapter. The term substrate–product selectivity can be used to describe such complex cases, 1.5. Setting the Scene which are conceivable for any type of selectiv- ity but have been reported mainly for In drug research and development, metabo- stereoselectivity. lism is of pivotal importance due to the inter- connectedness between pharmacokinetic and 1.4. Pharmacodynamic Consequences pharmacodynamic processes [14]. In vitro me- of Xenobiotic Metabolism
Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • Contig Protein Description Symbol Anterior Posterior Ratio
    Table S2. List of proteins detected in anterior and posterior intestine pooled samples. Data on protein expression are mean ± SEM of 4 pools fed the experimental diets. The number of the contig in the Sea Bream Database (http://nutrigroup-iats.org/seabreamdb) is indicated. Contig Protein Description Symbol Anterior Posterior Ratio Ant/Pos C2_6629 1,4-alpha-glucan-branching enzyme GBE1 0.88±0.1 0.91±0.03 0.98 C2_4764 116 kDa U5 small nuclear ribonucleoprotein component EFTUD2 0.74±0.09 0.71±0.05 1.03 C2_299 14-3-3 protein beta/alpha-1 YWHAB 1.45±0.23 2.18±0.09 0.67 C2_268 14-3-3 protein epsilon YWHAE 1.28±0.2 2.01±0.13 0.63 C2_2474 14-3-3 protein gamma-1 YWHAG 1.8±0.41 2.72±0.09 0.66 C2_1017 14-3-3 protein zeta YWHAZ 1.33±0.14 4.41±0.38 0.30 C2_34474 14-3-3-like protein 2 YWHAQ 1.3±0.11 1.85±0.13 0.70 C2_4902 17-beta-hydroxysteroid dehydrogenase 14 HSD17B14 0.93±0.05 2.33±0.09 0.40 C2_3100 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 ABHD5 0.85±0.07 0.78±0.13 1.10 C2_15440 1-phosphatidylinositol phosphodiesterase PLCD1 0.65±0.12 0.4±0.06 1.65 C2_12986 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta-1 PLCD1 0.76±0.08 1.15±0.16 0.66 C2_4412 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 PLCG2 1.13±0.08 2.08±0.27 0.54 C2_3170 2,4-dienoyl-CoA reductase, mitochondrial DECR1 1.16±0.1 0.83±0.03 1.39 C2_1520 26S protease regulatory subunit 10B PSMC6 1.37±0.21 1.43±0.04 0.96 C2_4264 26S protease regulatory subunit 4 PSMC1 1.2±0.2 1.78±0.08 0.68 C2_1666 26S protease regulatory subunit 6A PSMC3 1.44±0.24 1.61±0.08
    [Show full text]
  • 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers
    Japan. J. Pharmacol. 55, 359-366 (1991) 359 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers Hideki Ono, Hiroyuki Ito and Hideomi Fukuda' Departmentof Toxicologyand Pharmacology,Faculty of Pharmaceutical Sciences, TheUniversity of Tokyo,Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan 'Departmentof Pharmacology, Collegeof Pharmacy,Nihon University, 7-7-1Narashinodai, Funabashi, Chiba 274, Japan ReceivedJuly 28, 1990 AcceptedDecember 27, 1990 ABSTRACT Experiments were performed on spinalized rats transected at C1. In travenous administration of 2-phenylethylamine-HC1 (PEA-HC1) (0.3 and 1 mg/kg, i.v.) and methamphetamine-HC1 (MAP-HC1) (0.1 and 0.3 mg/kg, i.v.) increased the amplitude of the monosynaptic reflex (MSR). The increase of the MSR caused by PEA and MAP was antagonized by prazosin-HC1 and abolished by the pretreatment with reserpine (i.p.) and 6-hydroxydopamine (intracisternally, 14 days previously). A dopamine D, antagonist, SK&F 83566-HBr (0.01 mg/kg, i.v. ), and a D2 antagonist, YM-09151-2 (0.3 mg/kg, i.v.), did not antagonize the increasing effects produced by PEA and MAP. An inhibitor of type-B monoamine oxidase, (-)deprenyl-HC1 (1 mg/kg, i.v.), prolonged the effect of PEA but not that of MAP, suggesting that PEA alone, and not its metabolites, enhanced the MSR. These results suggest that PEA and MAP increase the amplitude of the MSR by releasing noradrenaline from the ter minals of descending noradrenergic fibers, and that PEA, an endogenous trace amine, has a mechanism of action similar to that of MAP.
    [Show full text]
  • Regulation of Xenobiotic and Bile Acid Metabolism by the Anti-Aging Intervention Calorie Restriction in Mice
    REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE By Zidong Fu Submitted to the Graduate Degree Program in Pharmacology, Toxicology, and Therapeutics and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Dissertation Committee ________________________________ Chairperson: Curtis Klaassen, Ph.D. ________________________________ Udayan Apte, Ph.D. ________________________________ Wen-Xing Ding, Ph.D. ________________________________ Thomas Pazdernik, Ph.D. ________________________________ Hao Zhu, Ph.D. Date Defended: 04-11-2013 The Dissertation Committee for Zidong Fu certifies that this is the approved version of the following dissertation: REGULATION OF XENOBIOTIC AND BILE ACID METABOLISM BY THE ANTI-AGING INTERVENTION CALORIE RESTRICTION IN MICE ________________________________ Chairperson: Curtis Klaassen, Ph.D. Date approved: 04-11-2013 ii ABSTRACT Calorie restriction (CR), defined as reduced calorie intake without causing malnutrition, is the best-known intervention to increase life span and slow aging-related diseases in various species. However, current knowledge on the exact mechanisms of aging and how CR exerts its anti-aging effects is still inadequate. The detoxification theory of aging proposes that the up-regulation of xenobiotic processing genes (XPGs) involved in phase-I and phase-II xenobiotic metabolism as well as transport, which renders a wide spectrum of detoxification, is a longevity mechanism. Interestingly, bile acids (BAs), the metabolites of cholesterol, have recently been connected with longevity. Thus, this dissertation aimed to determine the regulation of xenobiotic and BA metabolism by the well-known anti-aging intervention CR. First, the mRNA expression of XPGs in liver during aging was investigated.
    [Show full text]
  • Tyramine and Amyloid Beta 42: a Toxic Synergy
    biomedicines Article Tyramine and Amyloid Beta 42: A Toxic Synergy Sudip Dhakal and Ian Macreadie * School of Science, RMIT University, Bundoora, VIC 3083, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-3-9925-6627 Received: 5 May 2020; Accepted: 27 May 2020; Published: 30 May 2020 Abstract: Implicated in various diseases including Parkinson’s disease, Huntington’s disease, migraines, schizophrenia and increased blood pressure, tyramine plays a crucial role as a neurotransmitter in the synaptic cleft by reducing serotonergic and dopaminergic signaling through a trace amine-associated receptor (TAAR1). There appear to be no studies investigating a connection of tyramine to Alzheimer’s disease. This study aimed to examine whether tyramine could be involved in AD pathology by using Saccharomyces cerevisiae expressing Aβ42. S. cerevisiae cells producing native Aβ42 were treated with different concentrations of tyramine, and the production of reactive oxygen species (ROS) was evaluated using flow cytometric cell analysis. There was dose-dependent ROS generation in wild-type yeast cells with tyramine. In yeast producing Aβ42, ROS levels generated were significantly higher than in controls, suggesting a synergistic toxicity of Aβ42 and tyramine. The addition of exogenous reduced glutathione (GSH) was found to rescue the cells with increased ROS, indicating depletion of intracellular GSH due to tyramine and Aβ42. Additionally, tyramine inhibited the respiratory growth of yeast cells producing GFP-Aβ42, while there was no growth inhibition when cells were producing GFP. Tyramine was also demonstrated to cause increased mitochondrial DNA damage, resulting in the formation of petite mutants that lack respiratory function.
    [Show full text]
  • Selegiline) in Monkeys*
    Intravenous self-administration studies with /-deprenyl (selegiline) in monkeys* /-Deprenyl and its stereoisomer d-deprenyl did not maintain intravenous self-administration behavior in rhesus monkeys. In contrast, /-methamphetamine, the major metabolite of /-deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self-administration behavior. Treatment with /-deprenyl doses up to 1.0 mg/kg before self-administration sessions failed to alter self-administra- tion of either cocaine or /-methamphetamine. Thus /-deprenyl did not appear to have cocaine- or meth- amphetamine-like reinforcing properties in monkeys and was ineffective in altering established patterns of psychomotor-stimulant self-administration behavior. These results support clinical findings that de- spite long-term use of /-deprenyl for the treatment of Parkinson's disease by large numbers of patients, no instances of abuse have been documented. /-Deprenyl has recently been suggested as a potential med- ication for the treatment of various types of drug abuse, including cocaine abuse, but its failure to pro- duce selective effects in decreasing cocaine or methamphetamine self-administration behavior in the present experiments makes such an application seem unlikely. (CLIN PHARMACOL THER 1994;56:774-80.) Gail D. Winger, PhD,a Sevil Yasar, MD,b'd'e S. Steven Negus, PhD,a and Steven R. Goldberg, pIli/i d'e Ann Arbor, Mich., and Baltimore, Md. From the 'Department of Pharmacology, University of Michigan /-Deprenyl (selegiline) has been known for several
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Comparative Analysis of the Integument Transcriptomes Between Stick Mutant and Wild-Type Silkworms
    International Journal of Molecular Sciences Article Comparative Analysis of the Integument Transcriptomes between Stick Mutant and Wild-Type Silkworms Duan Tan †, Hai Hu †, Xiaoling Tong, Minjin Han, Songyuan Wu, Xin Ding, Fangyin Dai * and Cheng Lu * State Key Laboratory of Silkworm Genome Biology, Key Laboratory of Sericultural Biology and Genetic Breeding, Ministry of Agriculture, College of Biotechnology, Southwest University, Chongqing 400715, China; [email protected] (D.T.); [email protected] (H.H.); [email protected] (X.T.); [email protected] (M.H.); fl[email protected] (S.W.); [email protected] (X.D.) * Correspondence: [email protected] (F.D.); [email protected] (C.L.); Tel.: +86-23-6825-0793 (F.D. & C.L.) † These authors contributed equally to this work. Received: 19 September 2018; Accepted: 10 October 2018; Published: 14 October 2018 Abstract: In insects, the integument provides mechanical support for the whole body and protects them from infections, physical and chemical injuries, and dehydration. Diversity in integument properties is often related to body shape, behavior, and survival rate. The stick (sk) silkworm is a spontaneous mutant with a stick-like larval body that is firm to the touch and, thus, less flexible. Analysis of the mechanical properties of the cuticles at day 3 of the fifth instar (L5D3) of sk larvae revealed higher storage modulus and lower loss tangent. Transcriptome sequencing identified a total of 19,969 transcripts that were expressed between wild-type Dazao and the sk mutant at L5D2, of which 11,596 transcripts were novel and detected in the integument. Differential expression analyses identified 710 upregulated genes and 1009 downregulated genes in the sk mutant.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]
  • Amplitaq and Amplitaq Gold DNA Polymerase
    AmpliTaq and AmpliTaq Gold DNA Polymerase The Most Referenced Brand of DNA Polymerase in the World Date: 2005-05 Notes: Authors are listed alphabetically Genomics (105) Asanoma, K., T. Matsuda, et al. (2003). "NECC1, a candidate choriocarcinoma suppressor gene that encodes a homeodomain consensus motif." Genomics 81(1): 15. http://www.sciencedirect.com/science/article/B6WG1-47TF6BT- 3/2/fa37449c7379a083e7c7a5dc5f7670ae We isolated a candidate choriocarcinoma suppressor gene from a PCR-based subtracted fragmentary cDNA library between normal placental villi and the choriocarcinoma cell line CC1. This gene comprises an open reading frame of 219 nt encoding 73 amino acids and contains a homeodomain as a consensus motif. This gene, designated NECC1 (not expressed in choriocarcinoma clone 1), is located on human chromosome 4q11-q12. NECC1 expression is ubiquitous in the brain, placenta, lung, smooth muscle, uterus, bladder, kidney, and spleen. Normal placental villi expressed NECC1, but all choriocarcinoma cell lines examined and most of the surgically removed choriocarcinoma tissue samples failed to express it. We transfected this gene into choriocarcinoma cell lines and observed remarkable alterations in cell morphology and suppression of in vivo tumorigenesis. Induction of CSH1 (chorionic somatomammotropin hormone 1) by NECC1 expression suggested differentiation of choriocarcinoma cells to syncytiotrophoblasts. Our results suggest that loss of NECC1 expression is involved in malignant conversion of placental trophoblasts. Avraham, K. B., D. Levanon, et al. (1995). "Mapping of the mouse homolog of the human runt domain gene, AML2, to the distal region of mouse chromosome 4." Genomics 25(2): 603. http://www.sciencedirect.com/science/article/B6WG1-471W72M- 4N/2/f7891522e50770bac39f3b422467aaad Barr, F.
    [Show full text]